Manila Times Business
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
Rapidly Advancing Five IRD Programswith Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO Programs Expected to Enter Clinical Testing over the Next 12 to 18 Months Cash Runway into 2029 Expected to Fund Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers IRD Prevalence Across Select Global Markets Provides a Significant Commercial Opportunity Across Opus Genetics’ Pipeline RESEARCH TRIANGLE PARK, N.C., June 16, 2026 (GL
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Bookies.com Updates UK Apple Pay Casinos Guide to Reflect New UKGC Wagering Rules and Bonus Restrictions
2h ago
Falco’s Horne 5 Project: The Government of Québec confirms the project's progress within its environmental authorization process
2h ago
Element Plumbing, Heating, Air & Electrical Named Best Plumber in 2026 Best of Southern Utah Awards
2h ago
SIP, STYLE, TRAVEL, & SUNSHINE: THE SUMMER VIBES TAKING OVER 2026 in Discussion with YourUpdateTV
2h ago